Elekta offers asymmetric recovery potential as Elekta Evo adoption and more than SEK 500 M of savings could convert a temporarily weak top line into substantial margin-led value creation.
Elekta AB (publ) is a pioneering medical technology company that has shaped the global standards of precision radiation medicine since its founding in 1972 by Swedish neurosurgeon Lars Leksell [cite: 1, 2]. Operating primarily within the radiation oncology and neurosurgery markets, the company develops, manufactures, and supports state-of-the-art hardware, software, and integrated clinical workflow solutions [cite: 1]. Elekta’s business model is characterized by a dual-delivery framework: Solutions, which comprises advanced clinical hardware and software platforms, and Services, which delivers high-margin clinical training, preventative maintenance, remote troubleshooting, and continuous software upgrades to an expansive global installed base [cite: 1, 3, 4].
Historically, Solutions accounts for approximately 60% of net sales, while Services accounts for the remaining 40% [cite: 4]. This mix provides a resilient base of recurring revenues that mitigates the cyclicality of hospital capital expenditure cycles [cite: 4, 5]. During the first quarter of fiscal year 2026/27, Elekta transitioned its external financial reporting to five fully loaded regional profit-and-loss (P&L) divisions to align commercial accountability with internal management structures [cite: 6]. This structure consists of Europe, the Americas, China, Asia-Pacific and Japan (APJ), and Turkey, India, Middle East, and Africa (TIMEA) [cite: 6]. The table below provides a detailed breakdown of the net sales contribution and corresponding growth rates across these newly defined geographic segments for the first quarter of fiscal year 2026/27.
| Geographic Segment | Net Sales (SEK M) | Share of Total Net Sales (%) | Constant Currency Growth (%) | Reported Growth in SEK (%) |
|---|---|---|---|---|
| Europe | 1,202 | 34.0% | +5% | +4% |
| Americas | 1,088 | 30.8% | +2% | +2% |
| China | 432 | 12.2% | -16% | -13% |
| APJ (Asia-Pacific & Japan) | 414 | 11.7% | -12% | -16% |
| TIMEA (Turkey, India, Middle East, Africa) | 401 | 11.3% | -4% | -7% |
| Total Group | 3,536 | 100.0% | -2% | -3% |
Note: Geographically segmented net sales are based on Elekta's updated five-region organizational P&L structure [cite: 7].
Elekta's core product portfolio addresses several clinical modalities, encompassing external beam radiation therapy through linear accelerators (such as the Versa HD and the newly launched Elekta Evo), stereotactic radiosurgery through the Leksell Gamma Knife, magnetic resonance radiation therapy via the 1.5T Elekta Unity MR-Linac, localized brachytherapy systems, and comprehensive oncology informatics via the Elekta ONE software suite [cite: 1, 4, 5, 8]. The company’s primary customers include public and private hospitals, academic research institutions, specialized cancer clinics, and large multi-site healthcare networks [cite: 1].
Healthcare providers select Elekta over competitors due to its commitment to open-architecture software, which allows multi-vendor clinical environments to integrate seamlessly, and its clinical leadership in real-time online adaptive radiotherapy [cite: 1, 4, 5]. By utilizing advanced therapeutic options that optimize workflow efficiency and increase patient throughput, Elekta's clinical partners can deliver highly targeted, customized radiation treatments that improve patient survival rates and minimize adverse side effects [cite: 1, 5].
The economic engine of Elekta is driven by the global adoption of precision oncology solutions, the expansion of its clinical installed base, and the monetization of high-margin software upgrades and services [cite: 4, 5, 9]. Upfront sales of linear accelerators and stereotactic hardware establish a baseline footprint, which subsequently generates highly predictable, long-term service agreements under the Elekta Care program [cite: 1, 3, 4].
The primary near-term product driver is the global commercial launch of the Elekta Evo, a highly versatile, next-generation linear accelerator equipped with the advanced "Iris" high-definition CT imaging system [cite: 8, 10]. Following its recent regulatory clearances, including U.S. FDA clearance, the Elekta Evo is experiencing accelerated order conversion in mature markets where hospitals prioritize clinical throughput and real-time imaging [cite: 5, 9]. This platform addresses the industry trend of hypofractionation—delivering higher, more targeted doses of radiation in fewer clinical sessions—which enhances operational capacity for providers and improves convenience for patients [cite: 5].
Concurrently, the expansion of the Elekta ONE software platform, which integrates advanced treatment planning, oncology information, and AI-driven clinical workflow tools, allows the company to secure software-only upgrades within its multi-vendor installed base [cite: 1, 5, 8]. These software initiatives carry exceptional gross margins, driving corporate profitability independently of physical hardware shipments [cite: 9].
Elekta's economic moat is built on high customer switching costs, extensive intellectual property, and critical scale and distribution advantages [cite: 1, 5]. Linear accelerators and stereotactic hardware are multi-million dollar capital assets with useful lifespans of 10 to 15 years [cite: 1]. Once a healthcare facility standardizes its clinical protocols, software interfaces, treatment databases, and staff training on Elekta's oncology operating systems, the financial, operational, and retraining costs required to transition to a competitor are highly prohibitive [cite: 1, 5].
This high switching barrier is reinforced by Elekta’s deep intellectual property portfolio, particularly in stereotactic radiosurgery via the Gamma Knife and diagnostic-quality magnetic resonance guidance via the Elekta Unity MR-Linac [cite: 1]. Integrating a 1.5T MRI with a therapeutic linear accelerator without distorting the radiation beam requires immense technological precision, creating a steep entry barrier for new competitors [cite: 1, 4].
Additionally, medical devices must navigate complex global regulatory frameworks, including FDA 510(k) clearances and European Medical Device Regulation (MDR) certifications, which delay competitor entry by several years [cite: 5]. Elekta's vast global service footprint and clinical training networks act as a final structural moat, as public and private health systems require high-uptime service guarantees that only an established, scaled global peer can reliably provide [cite: 1, 3].
The long-term market opportunity for precision radiotherapy is driven by structural global tailwinds, particularly an aging worldwide population and a rising incidence of cancer [cite: 5]. Clinical guidelines indicate that approximately 50% of all cancer patients require radiotherapy as part of their curative or palliative care regimens [cite: 4, 5]. Despite this clinical consensus, access to radiation therapy remains highly underserved globally, particularly in developing nations, where the density of linear accelerators is far below medical recommendations [cite: 4].
In mature markets, such as North America and Europe, the addressable market is characterized by replacement cycles, software-driven diagnostic upgrades, and the adoption of real-time online adaptive systems [cite: 5, 9]. In emerging markets, including Latin America, China, and the TIMEA region, the opportunity is driven by greenfield clinical expansions and government-backed healthcare infrastructure spending [cite: 4, 5].
The global radiation oncology market is highly consolidated, functioning as an industry duopoly between Siemens Healthineers (following its acquisition of Varian Medical Systems) and Elekta [cite: 9, 11]. Other competitors, such as Accuray and specialty software providers like RaySearch Laboratories, operate primarily in specialized clinical niches [cite: 11]. Siemens-Varian holds a dominant overall market share, leveraging its massive corporate scale, diagnostic imaging portfolio, and institutional bundling capabilities to capture broad hospital system contracts [cite: 9, 11].
Elekta currently holds a strong competitive position in stereotactic radiosurgery and MR-guided radiation therapy [cite: 1, 4]. However, in the core linear accelerator market, the company has recently faced growth challenges, expanding slightly below the overall market growth rate due to customer delays in the United States while awaiting the regulatory rollout of the Elekta Evo [cite: 5, 8, 9]. As the Evo rollout gains commercial traction and order book conversion normalizes, Elekta is well-positioned to maintain its competitive share, though the aggressive marketing capabilities of Siemens Healthineers will continue to test Elekta’s pricing power and solution margins [cite: 5, 9].
Elekta announced its Q1 FY2026/27 interim financial results on August 27, 2026, marking the most current quarterly reporting period [cite: 3, 6]. The financial performance was characterized by a distinct divergence between slow top-line growth and major operational improvements driven by corporate restructuring [cite: 9].
In constant exchange rates, net sales decreased by 2% year-over-year [cite: 6, 9]. In reported terms, net sales in Swedish Krona (SEK) fell by 3% to SEK 3,536 M, compared to SEK 3,646 M in the first quarter of fiscal year 2025/26 [cite: 6, 12]. This reported revenue performance missed consensus analyst estimates by 2.6% [cite: 13]. The top-line deceleration was driven by Solutions sales, which contracted by 9% in constant currency (down 10% reported to SEK 1,628 M) due to delayed capital installations in the APJ and TIMEA regions, where healthcare budget constraints and geopolitical conflicts hindered delivery [cite: 7, 9]. In contrast, Services sales grew by 5% in constant currency (up 4% reported to SEK 1,909 M), showing consistent growth across all geographic regions [cite: 7, 9].
Despite the top-line headwind, Elekta achieved an operating beat due to structural margin expansion [cite: 9, 13]. The adjusted gross margin rose to 42.6%, representing a 560 basis point expansion compared to 37.0% in Q1 FY2025/26 [cite: 6, 9]. This improvement was driven by strong growth in software and services, global price increases, and lower costs of sales stemming from the company's new operating model [cite: 6, 9].
The gross margin also benefited from a SEK 53 M (150 basis points) refund of U.S. tariffs, with management forecasting an additional SEK 3 M in tariff refunds for the second quarter [cite: 6, 9]. Driven by the expanded gross margin and reduced selling and administrative expenses, adjusted EBIT rose 68% to SEK 395 M (vs. SEK 235 M in Q1 FY2025/26), corresponding to an adjusted EBIT margin of 11.2% (up from 6.5% in the prior year) [cite: 6]. Net income rose 146% to SEK 261 M (vs. SEK 106 M in Q1 FY2025/26), and reported earnings per share (EPS) reached SEK 0.69 (vs. SEK 0.28 in Q1 FY2025/26), beating analyst consensus expectations by 33% [cite: 6, 13].
The book-to-bill ratio remained healthy at 1.11, up from 1.05 in the prior year, supported by strong order intake for the Elekta Evo [cite: 6, 9]. Free cash flow before dividends and M&A was seasonally negative at SEK -266 M, though it improved by SEK 154 M compared to SEK -420 M in Q1 FY2025/26, supported by higher underlying earnings and disciplined R&D capitalized investments [cite: 6, 9].
During the Q1 earnings conference call, CEO Jakob Just-Bomholt and CFO Klara Eiritz reiterated Elekta’s guidance for the full fiscal year 2026/27 [cite: 9, 14]. The company expects constant-currency sales growth of 2% to 4% and an adjusted EBIT margin of 12.5% to 13.5% [cite: 15, 16].
Management emphasized that the group is executing its three-phase turnaround strategy, with the current fiscal year heavily focused on Phase 2: improving profitability [cite: 6, 9]. The new operating model, which involved cutting approximately 450 positions and simplifying regional divisions, has surpassed expectations, delivering more than SEK 500 M in annualized cost savings [cite: 9, 17].
Management noted that stricter order acceptance criteria implemented in late fiscal year 2025/26 are improving the margin quality of the backlog, even if they temporarily limit near-term order growth [cite: 9, 18]. On regional dynamics, management reported that China is starting to normalize after weaker order intake caused by the government's anti-corruption campaign, while capital expenditures in mature markets are recovering [cite: 5, 9].
The stock market reacted to the Q1 results with caution, focusing on the top-line contraction rather than the margin improvements [cite: 9]. On the day of the announcement, the share price fell 5.57% in pre-market/intraday trading, closing near SEK 49.02, which lies toward the lower end of its 52-week range of SEK 42.20 to SEK 66.60 [cite: 9, 19].
Following the earnings release and the subsequent Annual General Meeting (AGM) on September 3, 2026, analysts adjusted their models [cite: 3, 20]. The average 12-month analyst consensus price target was adjusted to SEK 53.79 (representing a 7.5% reduction from the previous target of SEK 58.12) [cite: 20]. More recent institutional consensus estimates have updated the average analyst target price to SEK 59.69 [cite: 11].
To establish a clear connection between valuation and Elekta's core business model, investors must monitor several key operational and financial variables:
* Five-Year Sales Growth Profile: Elekta's historical five-year sales CAGR (FY2020/21 to FY2025/26) was 3.97%, reflecting flat capital sales offset by resilient service expansions [cite: 19, 21]. Long-term valuation remains highly sensitive to whether the company can elevate this growth rate to its mid-term target of mid-single-digit growth through FY2028/29 [cite: 15, 16].
* Order Backlog Integrity and Quality: In FY2025/26, management conducted a rigorous order backlog and balance sheet review [cite: 5]. This review resulted in the cancellation of SEK 2.2 B in lower-quality, inactive orders and led to non-cash items affecting comparability of SEK 1.4 B (representing impairments on capitalized R&D and goodwill) [cite: 5, 18]. This cleanup has improved the visibility of future solution revenues, but temporarily slowed near-term order growth [cite: 9, 18].
* Operational Margin Leverage: Having completed its organizational downsizing, the company expects to generate sustained operating leverage [cite: 17, 18]. If Elekta can maintain its annualized cost savings above SEK 500 M while converting its order backlog, it is positioned to achieve its mid-term target of an adjusted EBIT margin of 14% to 16% by FY2028/29 [cite: 9, 16, 17].
Elekta faces operational execution risks related to product delivery and installation timelines [cite: 7, 9]. Because linear accelerators require complex clinical site preparations and local regulatory licensing, unexpected delays can lead to working capital buildup and deferred revenue recognition [cite: 1, 9]. This risk is heightened for the next-generation Elekta Evo platform, where any software or hardware integration bottlenecks could slow the conversion of orders into physical installations [cite: 5, 9].
On a competitive level, Elekta risks losing market share to Siemens Healthineers [cite: 9, 11]. Siemens' ability to offer bundle discounts on diagnostic imaging and treatment planning software could margin-squeeze Elekta's solutions, particularly within large hospital purchasing groups in North America and Western Europe [cite: 5, 8].
The company’s customer concentration is low, but its revenues are sensitive to global healthcare capital expenditure budgets [cite: 7, 9]. In regions like Asia-Pacific and Japan, capital constraints have recently limited hospital equipment investments, leading to a 12% decline in Elekta’s regional constant-currency sales in Q1 FY2026/27 [cite: 7].
Regulatory hurdles also pose operational risks [cite: 5, 9]. Delays in receiving CE MDR or FDA approvals for new adaptive workflow features or advanced treatment planning algorithms could postpone key product launches and extend R&D amortization periods [cite: 5, 8, 18].
Additionally, Elekta faces modern cybersecurity and information security risks [cite: 3]. The company recently identified a cybersecurity incident involving unauthorized access to its IT environment, resulting in the extraction of certain customer business contact details [cite: 3]. While this specific incident did not affect clinical software operations, any future breach targeting oncology information networks (such as Elekta ONE) could cause software downtime, liability issues, and damage to customer relationships [cite: 1, 3].
Elekta faces capital allocation and balance sheet risks, particularly regarding its dividend coverage [cite: 20]. The Board proposed an unchanged dividend of SEK 2.40 per share for the fiscal year, representing an aggregate payout of SEK 917 M [cite: 18].
Although this payout is supported by positive cash flows (free cash flow after continuous investments was SEK 1,392 M in FY2025/26), the company reported a GAAP net loss of SEK -517 M and a loss per share of SEK -1.36 for FY2025/26 due to heavy non-cash R&D write-downs and restructuring charges [cite: 6, 18, 22]. This high payout ratio limits the company’s cash retention and its ability to fund early-stage R&D initiatives [cite: 6, 9].
Furthermore, macroeconomic factors such as trade tariffs and currency fluctuations can impact the business [cite: 5, 9]. While US tariff refunds of SEK 53 M supported margins in Q1 FY2026/27, future changes in international trade policies could increase input costs [cite: 6, 9]. Additionally, adverse foreign exchange movements, particularly a strengthening Swedish Krona relative to the U.S. Dollar and Euro, can impact reported revenues and margins [cite: 23].
To evaluate Elekta’s long-term valuation potential over a five-year horizon (representing fiscal year 2030/31, with FY2025/26 as Year 0), this analysis models three distinct scenarios driven by fundamental operational and financial assumptions.
The valuation model utilizes a current share count of 383.0 million shares outstanding (excluding treasury shares) and a current base share price of SEK 49.02 as of September 2026 [cite: 5, 19, 21]. Historical five-year sales growth from FY2020/21 (SEK 13,763 M) to FY2025/26 (SEK 16,718 M) was 3.97% [cite: 19, 21]. All scenarios assume a stable corporate tax rate of 25.0% and annual net interest expenses of SEK 200 M based on current leverage [cite: 18, 21].
The Base Case assumes that Elekta successfully executes its mid-term turnaround plan [cite: 9].
* Revenue Growth: Net sales grow at a CAGR of 4.0% over the next five years, reaching SEK 20,340.0 M by Year 5, supported by the steady international rollout of the Elekta Evo and robust service demand [cite: 9, 16, 21].
* Operating Margin: The adjusted EBIT margin expansions from the new operating model are sustained, reaching 14.5% (the midpoint of management’s mid-term target of 14% to 16%) [cite: 9, 15, 16].
* Earnings Projection: Adjusted EBIT in Year 5 reaches SEK 2,949.3 M [cite: 21]. Deducting annual net interest of SEK 200 M yields pre-tax income of SEK 2,749.3 M [cite: 21]. Applying the 25% tax rate results in projected Net Income of SEK 2,062.0 M, equivalent to a Year 5 EPS of SEK 5.38 [cite: 21].
* Valuation Multiple: An exit P/E multiple of 18.0x is applied, in line with historical averages [cite: 21].
* Projected Share Price and Return: This yields a Year 5 projected share price of SEK 96.91, representing a total return of 97.7% and an annualized return of 14.6% [cite: 21].
The High Case models an accelerated growth path, driven by market share gains and rapid clinical adoption of high-margin adaptive radiotherapy [cite: 5, 15].
* Revenue Growth: Net sales grow at an accelerated CAGR of 6.5%, reaching SEK 22,905.1 M by Year 5, driven by strong adoption of the Elekta Evo in the United States and a recovery in China's capital expenditures [cite: 5, 9, 21].
* Operating Margin: The adjusted EBIT margin reaches the high end of targets at 16.0% due to favorable product mix, including high-margin software upgrades and digital ecosystem revenues [cite: 15, 16].
* Earnings Projection: Adjusted EBIT in Year 5 reaches SEK 3,664.8 M [cite: 21]. Subtracting interest of SEK 200 M yields pre-tax income of SEK 3,464.8 M, resulting in net income of SEK 2,598.6 M and an EPS of SEK 6.78 [cite: 21].
* Valuation Multiple: A premium exit P/E multiple of 22.0x is applied, reflecting stronger organic growth and leadership in adaptive oncology software [cite: 21].
* Projected Share Price and Return: This yields a Year 5 projected share price of SEK 149.27, representing a total return of 204.5% and an annualized return of 24.9% [cite: 21].
The Low Case models a slower growth path due to competitive pressure and budget constraints [cite: 7, 9].
* Revenue Growth: Net sales grow at a CAGR of 1.0%, reaching SEK 17,570.8 M by Year 5, as market share is lost to Siemens-Varian and emerging markets experience prolonged installation delays [cite: 7, 9, 21].
* Operating Margin: The adjusted EBIT margin drops to 10.0%, as pricing pressure and lower hardware volumes offset the cost savings from the simplified operating model [cite: 18, 21].
* Earnings Projection: Adjusted EBIT in Year 5 reaches SEK 1,757.1 M [cite: 21]. Deducting interest of SEK 200 M yields pre-tax income of SEK 1,557.1 M, resulting in net income of SEK 1,167.8 M and an EPS of SEK 3.05 [cite: 21].
* Valuation Multiple: A discounted P/E multiple of 13.0x is applied, reflecting multiple compression from slow growth and market share erosion [cite: 21].
* Projected Share Price and Return: This yields a Year 5 projected share price of SEK 39.64, representing a total return of -19.1% and an annualized return of -4.2% [cite: 21].
| Scenario | Year 5 Revenue (SEK M) | Margin Assumption (EBIT %) | Exit P/E Multiple | Current Share Price (SEK) | Implied Future Price (SEK) | 5-Year Total Return (%) | Annualized Return (%) | Probability Weight |
|---|---|---|---|---|---|---|---|---|
| High Case | 22,905.1 | 16.0% | 22.0x | 49.02 | 149.27 | +204.5% | +24.9% | 20.0% |
| Base Case | 20,340.0 | 14.5% | 18.0x | 49.02 | 96.91 | +97.7% | +14.6% | 50.0% |
| Low Case | 17,570.8 | 10.0% | 13.0x | 49.02 | 39.64 | -19.1% | -4.2% | 30.0% |
| Weighted | - | - | - | 49.02 | 90.20 | +84.0% | +13.0% | 100.0% |
Note: Year 5 financials, returns, and the weighted target price of SEK 90.20 are based on model projections [cite: 19, 21].
ASYMMETRIC RETURN POTENTIAL
To evaluate the long-term investment profile of Elekta, each fundamental operational domain has been scored from 1 to 10.
The Leksell family remains highly committed, controlling 30.23% of the total voting rights in the company, ensuring long-term oversight [cite: 5]. The share capital of Elekta AB consists of 14,980,769 Series A shares (carrying 10 votes per share) and 368,587,640 Series B shares (carrying 1 vote per share) [cite: 5]. Under the executive guidelines approved at the AGM, the CEO's variable pay is structured as Short-Term Incentives (STI) and Long-Term Incentives (LTI) [cite: 24]. The STI criteria are weighted: 30% on Group Revenue (threshold SEK 17,191 M, cap SEK 24,831 M), 40% on Group operating margin (EBIT%) (threshold 11.7%, cap 16.9%), and 30% on Group cash flow (threshold SEK 1,040 M, cap SEK 1,952 M) [cite: 24]. LTI includes ESG metrics [cite: 5]. These targets align executive pay with shareholder returns. However, the recent management transition and the appointment of a new CFO and COO require further execution seasoning to build market credibility [cite: 5].
* Score: 7 / 10
Highly recurring service and software sales represent roughly 40% of the overall business, providing a strong cash-flow foundation [cite: 4, 23]. While the core capital installations (Solutions) are cyclical, the order book contains high-quality contracts following a rigorous backlog review that removed SEK 2.2 B in lower-performing orders [cite: 5].
* Score: 8 / 10
Elekta occupies a strong position in highly specialized niches, such as intracranial radiosurgery (Gamma Knife) and MR-guided radiotherapy (Unity) [cite: 1, 4]. However, in the high-volume linear accelerator market, the company continues to experience competitive pressure from the market leader, Siemens-Varian, and is currently growing below the overall market average [cite: 9].
* Score: 6 / 10
The mid-term outlook is supported by positive demographics and the clinical roll-out of the Elekta Evo [cite: 5, 9]. Management's guidance for mid-single-digit CAGR through FY2028/29 is achievable, provided that the US market recovers and APAC capital constraints ease [cite: 9, 15, 16].
* Score: 7 / 10
Leverage remains manageable, with net debt ending at SEK 3,191 M [cite: 18]. Free cash flow yield is strong at 11%, driven by disciplined working capital and reduced R&D capitalization [cite: 9, 23]. However, seasonal working capital swings can put near-term pressure on cash generation [cite: 9].
* Score: 7 / 10
Cancer care is a non-discretionary clinical need [cite: 5]. The long-term durability of Elekta's installed base, along with its extensive service contracts, makes the business highly resilient to short-term economic downturns [cite: 4, 5]. The primary risk is a prolonged clinical transition away from radiation toward systemic therapies, though radiotherapy remains a cornerstone of standard oncological protocols [cite: 5].
* Score: 8 / 10
The Board proposed an unchanged dividend of SEK 2.40 per share for the fiscal year, representing a cash payment of SEK 917 M [cite: 2, 18]. Although this dividend is covered by operating cash flows, the company reported a GAAP net loss of SEK -517 M in FY2025/26 due to heavy non-cash R&D write-downs [cite: 6, 22]. Retaining more capital would provide higher financial flexibility to fund breakthrough innovations.
* Score: 6 / 10
Institutional analysts are cautious regarding Elekta's short-term growth prospects, as demonstrated by target price revisions down to SEK 53.79 [cite: 20]. However, value-oriented research groups, including Morningstar, note a wide economic moat and estimate that the stock trades at a significant discount to its fair value of SEK 108.00 [cite: 25].
* Score: 6 / 10
The company is demonstrating strong progress under its turnaround plan, with adjusted gross margins reaching 42.6% in the latest quarter [cite: 6, 9]. However, reported GAAP margins remain volatile due to R&D impairments and restructuring charges related to the change in the operating model [cite: 6, 18].
* Score: 7 / 10
Elekta has maintained continuous dividend payments for over 20 consecutive years, indicating a long-term commitment to shareholder returns [cite: 23]. Nonetheless, long-term organic growth has been inconsistent, often falling short of initial mid-term targets [cite: 4, 8, 26].
* Score: 6 / 10
| Domain | Score (1-10) | Key Driver |
|---|---|---|
| Management Alignment | 7 | Strong alignment of variable pay metrics with revenue and cash targets [cite: 24]. |
| Revenue Quality | 8 | Resilient recurring revenue base from software and service upgrades [cite: 4, 9]. |
| Market Position | 6 | Solid positions in radiosurgery; competitive headwinds in linear accelerators [cite: 1, 9]. |
| Growth Outlook | 7 | Opportunities from Elekta Evo adoption and hypofractionation trends [cite: 5, 9]. |
| Financial Health | 7 | Manageable net debt offset by seasonal working capital requirements [cite: 9, 18]. |
| Business Viability | 8 | Non-discretionary clinical demand and highly stable long-term therapy models [cite: 5]. |
| Capital Allocation | 6 | Steady dividend maintained despite GAAP net income pressures [cite: 6, 18]. |
| Analyst Sentiment | 6 | Conservatism regarding top-line growth vs. recognition of discount to fair value [cite: 9, 25]. |
| Profitability | 7 | Underlying progress in adjusted margins; GAAP earnings impacted by write-downs [cite: 6, 18]. |
| Track Record | 6 | Over two decades of dividend payments; historical organic growth is uneven [cite: 8, 23]. |
| Overall Blended Score | 6.8 / 10 | Steady operational recovery supported by a resilient business model. |
Note: Scorecard represents a qualitative synthesis of fundamental attributes [cite: 4, 5, 6, 18, 24].
STABILIZING OPERATIONAL PROFILE
The fundamental analysis of Elekta AB reveals an undervalued leader in precision radiation medicine [cite: 1, 25]. The company is currently executing its three-phase turnaround strategy, focusing on operational simplification and cost control [cite: 6, 9]. While top-line growth is temporarily constrained by installation schedules and capital spending pauses in emerging regions, the company’s underlying margins have improved [cite: 7, 9]. Adjusted gross margins expanded to 42.6% in the latest quarter, driven by over SEK 500 M in annualized cost savings from its new operating model [cite: 6, 9, 17].
Key catalysts for valuation recovery over the medium term include:
* The Commercial Adoption of the Elekta Evo: The platform is beginning to drive order conversion in the United States and Europe, supported by growing clinical demand for real-time online adaptive therapies [cite: 5, 9].
* Stabilization of the Chinese and APJ Markets: As healthcare capital budgets recover and the impact of domestic anti-corruption programs normalizes, capital installations are expected to accelerate [cite: 5, 9].
* Backlog Conversion and Operating Leverage: The transition to a streamlined regional P&L model will continue to support operating leverage as higher-margin software solutions represent a larger portion of the overall sales mix [cite: 6, 18].
Although execution, competitive, and foreign exchange risks remain, the stock’s current market price of SEK 49.02 represents a significant discount to Morningstar's fair value estimate of SEK 108.00 and is well below the probability-weighted 5-year target price of SEK 90.20 [cite: 19, 21, 25]. As Elekta translates its improved operational efficiency into sustained organic growth, substantial valuation recovery is anticipated [cite: 9, 21].
ASYMMETRIC RECOVERY PROFILE
Elekta's stock price has experienced downward technical momentum, trading at SEK 49.02 [cite: 19]. This level places the stock below its 50-day simple moving average of SEK 50.68 and its 200-day simple moving average of SEK 50.11, indicating a prevailing bearish trend [cite: 27].
However, technical oscillators show signs of exhaustion, with the Relative Strength Index (RSI) at 21.17, indicating oversold conditions [cite: 27]. While the MACD of -0.980 suggests near-term caution, the oversold indicators suggest potential for short-term price stabilization, provided that order book conversion and clinical shipments meet expectations in the upcoming quarters [cite: 9, 27].
OVERSOLD TECHNICAL CONSOLIDATION
View Elekta AB (publ) (EKTA-B.ST) stock page
Loading the interactive version of this report…